Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects

NCT01534403 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Epratuzumab

Sponsor

UCB Pharma